Penumbra, Inc. (NYSE:PEN) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 10.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 597,077 shares of the company's stock after selling 71,796 shares during the quarter. Janus Henderson Group PLC owned about 1.56% of Penumbra worth $141,796,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. UMB Bank n.a. lifted its holdings in shares of Penumbra by 57.4% in the fourth quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $46,000 after buying an additional 70 shares in the last quarter. Hurley Capital LLC purchased a new stake in Penumbra in the 4th quarter worth approximately $56,000. Huntington National Bank raised its position in shares of Penumbra by 138.7% in the fourth quarter. Huntington National Bank now owns 265 shares of the company's stock worth $63,000 after buying an additional 154 shares in the last quarter. Mather Group LLC. boosted its position in shares of Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company's stock valued at $73,000 after acquiring an additional 208 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its stake in Penumbra by 25.0% in the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock worth $89,000 after buying an additional 75 shares in the last quarter. 88.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Penumbra in a research note on Wednesday, February 19th. Royal Bank of Canada upped their target price on Penumbra from $315.00 to $330.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Piper Sandler reissued an "overweight" rating and issued a $330.00 price target (up from $250.00) on shares of Penumbra in a research note on Wednesday, February 19th. Wells Fargo & Company lifted their price objective on Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. Finally, JPMorgan Chase & Co. lifted their price objective on Penumbra from $230.00 to $285.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $302.40.

Insider Transactions at Penumbra

In other news, Director Thomas Wilder sold 360 shares of the stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80. Following the sale, the director now owns 4,533 shares of the company's stock, valued at approximately $1,199,341.14. This represents a 7.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Adam Elsesser sold 61,600 shares of Penumbra stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $283.59, for a total transaction of $17,469,144.00. Following the completion of the transaction, the chief executive officer now owns 16,376 shares of the company's stock, valued at $4,644,069.84. This trade represents a 79.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold 159,996 shares of company stock worth $45,228,678 in the last 90 days. Insiders own 4.20% of the company's stock.

Penumbra Stock Up 2.1%

Shares of Penumbra stock traded up $5.78 during trading on Friday, reaching $281.10. The company's stock had a trading volume of 711,568 shares, compared to its average volume of 438,992. The company has a market cap of $10.89 billion, a price-to-earnings ratio of 826.76, a P/E/G ratio of 2.83 and a beta of 0.53. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The company has a 50-day simple moving average of $279.00 and a two-hundred day simple moving average of $262.86. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $310.00.

Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. The business had revenue of $324.14 million for the quarter, compared to analyst estimates of $315.72 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The business's revenue was up 16.3% on a year-over-year basis. During the same period last year, the company posted $0.41 EPS. As a group, equities analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.